In 1998, Clay Siegall was among the co-founders of Seattle Genetics that gave him the position of becoming the companies Chief Executive Officer, the president and the board members he was the chairman. Clay had the training in science that’s why at Seattle Genetics he built the company in a way that it will emphasis of the cancer therapies on the foundation that the team was to come up with rigorous research, innovations, and development of the best drug with one thing in mind that is helping the patients. Clay Siegall has been efficiently offering his leadership skills to the company that has overseen the position that they have in developing the antibody- drug and getting the approval from the 2011 FDA on the first product they developed the ADC, ADCETRIS. The reason why ADCETRIS is the drug that has been approved in 65 countries, is that the collaboration that took place with Takeda Pharmaceuticals Company is overseen the growth in awareness.
Under the leadership on Dr. Siegall, there has been the entering of the multiple strategic licenses by the Seattle genetics because of the ADC technology, which has been successful because it has earned the company $350 million. In the Seattle Genetic capital raising activities, Dr. Siegall has been leading the company, which has resulted in getting $1.2 billion in the public and private Financings, the one that is commonly known is the public offering in 2001.
Before the co-founding of Seattle Genetics from 1991 to 1997 Dr. Siegall worked at Bristol-Myers Squibb, and in 1988 to 1991 he worked at the National Institute of Health. In the Ultragenyx Pharmaceutical and Washington Roundtable, he is among the board of directors. In his career life, he has received so many awards that have recognized his good works. Because he makes sure that the needs of the patient will be the priority. That has resulted in him receiving the Alumnus of the year for the computer that was in 2013 and in 2012 he got the Pacific Northwest Ernst award. He has written more than 70 publications. He attended the George Washington University where he received his Ph.D. in genetics.